Loading, Please Wait...
Call to feature thought leaders discussing mitochondria and mitochondrial-drived peptides as a potential source of novel therapeutics
Call and webcast scheduled for May 2, 2019; 10:30-11:45am EDT
MENLO PARK, Calif., April 23, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that the Company will host a Key Opinion Leader conference call and webcast on May 2, 2019 featuring thought leaders who will discuss the role of mitochondria in health and aging, and mitochondrial-derived peptides (MDPs) as a novel source of potential therapeutics for a host of major age-related diseases.
CohBar's management team will also provide an overview of the company’s mitochondria based therapeutics platform, from identification of peptides encoded within the mitochondrial genome to discovery and development of novel peptide analogs with therapeutic potential, and its lead clinical program targeting NASH and obesity. The presentation will be followed by a question and answer session.
David A. Sinclair, Ph.D.
David A. Sinclair, Ph.D. is a tenured Professor of Genetics at Harvard Medical School, co-Director of the Paul F. Glenn Center for the Biology of Aging Research at Harvard Medical School, and Conjoint Professor at the University of New South Wales, Sydney. He is best known for his work on genes and small molecules that delay aging, including the Sirtuins, NAD precursors, and other epigenetic modifiers. Dr. Sinclair is regarded as one of the world’s leading researchers on aging and age-associated diseases, with key contributions to understanding why we age and how to slow and even reverse the process. He has co-founded multiple biotechnology and genomics companies working on aging, neurological, metabolic, infectious and rare diseases, including CohBar and Life Biosciences. Dr. Sinclair serves as co-chief editor of the scientific journal Aging and has received 35 honors including being one of Australia's leading scientists under 45, the Australian Medical Research Medal, the NIH Director’s Pioneer Award, TIME magazine’s list of the “100 Most Influential People in the World” (2014) and the “Top 50 People in Healthcare” (2018). He was elected an Officer of the Order of Australia in 2018 and is a member of CohBar’s Scientific Advisory Board.
Pinchas Cohen, MD
Pinchas Cohen, MD is the dean of the USC Leonard Davis School of Gerontology, executive director of the Ethel Percy Andrus Gerontology Center, and holder of the William and Sylvia Kugel Dean’s Chair in Gerontology. He also holds joint appointments at the Keck School of Medicine of USC and in the Department of Biological Sciences at the USC Dornsife College of Letters, Arts and Sciences. Dr. Cohen is an expert in the study of mitochondrial peptides and their possible therapeutic benefits for diabetes, Alzheimer’s, and other diseases related to aging, and holds several patents for novel peptides. He has received numerous awards for his research, including a National Institute of Aging “EUREKA” Award, the National Institutes of Health Director Transformative RO1 Grant, and the Glenn Award for Research in Biological Mechanisms of Aging. Dr. Cohen is president of the Growth Hormone Society and has served on the Endocrine Society Steering Committee. He sits on multiple NIH study sections and on several editorial boards as well as on the American Federation of Aging Research Board. Dr. Cohen is a founder and director of CohBar.
Conference call and webcast details:
Date: May 2, 2019
Time: 10:30-11:45 am EDT (7:30-8:45 am PDT)
To access the conference audio:
Dial-in U.S. and Canada: (888) 394-8218
Dial-in International: (323) 701-0225
Conference ID No.: 8273599
To access the webcast and slide presentation:
To access the webcast and slide peresentation, please click on the following link:
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), obesity, Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs. For additional company information, please visit www.cohbar.com.
This news release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the therapeutic potential of CohBar’s lead candidate program and other mitochondria based therapeutics, the potential for additional discoveries, and our plans and expectations regarding intellectual property protection. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. Such assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Investor and Media Contact:
Jon Stern, COO